Form 4 for AMGN Amgen
Accepted 2022-11-08 00:00:00 ET · period of report 2022-11-05 · accession 0001127602-22-025156 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-08 | 2022-11-05 | AMGN | Louie Linda H. | VP, CAO, Fin | F - Tax | $269.04 | -45 | 9,278 | -0.5% | -$12.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-05 | F | D | 45 | $269.04 | 9,278 | D | — | — | (F1) 45 shares issuable upon the vesting of Restricted Stock Units (RSUs) and related Dividend Equivalents (DEs) on 11/5/2022 were withheld by the Company to cover related tax withholding obligations. (F3) These shares include 108 DEs granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. (F2) These shares include the following RSUs granted under the Company's equity plans: 67 RSUs which vest on 5/3/2023; 114 RSUs which will vest in installments of 56 on 5/5/2023 and 58 on 5/5/2024; 974 RSUs which vest in installment of 479 on 11/2/2023 and 495 on 11/2/2024; 300 RSUs which vest in two installments of 99 on 4/30/2023 and 4/30/2024 and one installment of 102 on 4/30/2025; 175 RSUs which will vest on 11/5/2023; and 433 RSUs which will vest in installments of 142 on 5/2/2024, 143 on 5/2/2025, and 148 on 5/5/2026.. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. |